-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
DENV-IN-5
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2762302-75-8.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2762302-75-8 |
| Description | DENV-IN-5 (Compound 4b) is a dengue virus (DENV) inhibitor with EC50s of 1.47, 9.23, 7.08 and 8.91 μM against DENV-I - IV replication, respectively. DENV-IN-5 also inhibits HIV-1IIIB strain with an EC50 of 0.1512 μM. |
Product Information
| Synonyms | DENV-IN-5|SCHEMBL21346327|HY-143274|CS-0434019|2-[[4-chloro-5-(3,4-difluorophenyl)-1H-pyrazol-3-yl]methylsulfanyl]-4-(cyclohexylmethyl)-5-ethyl-1H-pyrimidin-6-one |
| Molecular Weight | 516.66 |
| Molecular Formula | C23H25ClF2N4OS |
| Canonical SMILES | CCC1=C(N=C(NC1=O)SCC2=C(C(=NN2)C3=CC(=C(C=C3)F)F)Cl)CC4CCCCC4 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 746 |
| Exact Mass | 478.1405666 |
| In Vitro | DENV-IN-4 (compound 15) (0.064-200 μM; 3 days) has antiviral effects independent of its toxicity (DENV EC50 = 4.79 μM, Vero CC50>100, SI>20.9). DENV-IN-4 (3.125-50 μM in Vero and 3.75-30 μM in A549 and Huh-7; 48 h) inhibits the expression level of DENV2 and is concentration-dependent with a smoother inhibition curve in Vero. DENV-IN-4 (7.5 and 15 μM; 48 h) potently inhibits DENV infection in Vero cells and is completely inhibited at 15 μM. DENV-IN-4(0-15μM; 48 h) inhibits the production of DENV2E protein in Vero cells with good concentration dependence. Result: The antiviral effect of DENV-IN-4 was shown to be independent of its toxicity (Vero EC50 = 4.79 μM, CC50>100, SI>20.9). |
| Target | HIV (IIIB): 0.1512 μM (EC50) DENV-I: 1.47 μM (EC50) DENV-III: 7.08 μM (EC50) DENV-IV: 8.91 μM (EC50) DENV-II: 9.23 μM (EC50) |
| XLogP3-AA | 6.3 |
